JP2003507338A - レクチン補体経路（ｌｃｐ）のインヒビターおよびその使用 - Google Patents

レクチン補体経路（ｌｃｐ）のインヒビターおよびその使用

Info

Publication number
JP2003507338A
JP2003507338A JP2001516557A JP2001516557A JP2003507338A JP 2003507338 A JP2003507338 A JP 2003507338A JP 2001516557 A JP2001516557 A JP 2001516557A JP 2001516557 A JP2001516557 A JP 2001516557A JP 2003507338 A JP2003507338 A JP 2003507338A
Authority
JP
Japan
Prior art keywords
mbl
receptor antagonist
lectin
complement activation
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001516557A
Other languages
English (en)
Japanese (ja)
Inventor
グレゴリー エル． スタール，
ロバート レコウスキー，
Original Assignee
ザ ブリグハム アンド ウイメンズ ホスピタル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ブリグハム アンド ウイメンズ ホスピタル インコーポレイテッド filed Critical ザ ブリグハム アンド ウイメンズ ホスピタル インコーポレイテッド
Publication of JP2003507338A publication Critical patent/JP2003507338A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2001516557A 1999-08-13 2000-08-14 レクチン補体経路（ｌｃｐ）のインヒビターおよびその使用 Withdrawn JP2003507338A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14881599P 1999-08-13 1999-08-13
US60/148,815 1999-08-13
PCT/US2000/022123 WO2001012212A1 (fr) 1999-08-13 2000-08-14 Inhibiteurs de la voie du complement a lectine (lpc) et utilisation de ceux-ci

Publications (1)

Publication Number Publication Date
JP2003507338A true JP2003507338A (ja) 2003-02-25

Family

ID=22527516

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001516557A Withdrawn JP2003507338A (ja) 1999-08-13 2000-08-14 レクチン補体経路（ｌｃｐ）のインヒビターおよびその使用

Country Status (5)

Country Link
EP (1) EP1204419A1 (fr)
JP (1) JP2003507338A (fr)
AU (1) AU781805B2 (fr)
CA (1) CA2380979A1 (fr)
WO (1) WO2001012212A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US7273925B1 (en) 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
CN1449440A (zh) 2000-07-13 2003-10-15 詹斯·C·詹斯尼厄斯 Masp－2,一种补体固定酶及其用途
DE10130985B4 (de) 2001-06-27 2004-03-18 B.R.A.H.M.S Ag Verfahren zur Diagnose von Sepsis und schweren Infektionen unter Bestimmung löslicher Cytokeratin-1-Fragmente
US20060140939A1 (en) 2003-02-21 2006-06-29 Fung Sek C M Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
EP2374819B1 (fr) 2003-05-12 2017-03-22 Helion Biotech ApS Anticorps contre MASP-2
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
EP2529746A1 (fr) 2005-06-06 2012-12-05 Girish J. Kotwal Méthodes de traitement ou de prophylaxie de lésions de réperfusion
US8524453B2 (en) 2006-02-10 2013-09-03 The Brigham And Woman's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
WO2009108153A1 (fr) * 2008-02-29 2009-09-03 The Brigham And Women's Hospital, Inc. Procédés et compositions destinés à la régulation de l'activation du complément associée à la voie lectine du complément (lcp) dans la lésion myocardique hyperglycémique
PT2488203T (pt) 2009-10-16 2017-03-10 Univ Leicester Métodos para tratamento de coagulação intravascular disseminada através da inibição da activação do complemento dependente de masp-2
US20170137537A1 (en) * 2015-11-09 2017-05-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500023L (sv) * 1994-05-17 1995-11-18 Beki Ab Sätt att detektera cancer
DE19806185C2 (de) * 1998-02-02 1999-11-18 Biogenes Gmbh Immunoassay und Testkit zur Bestimmung von fucosyliertem Protein in einer biologischen Probe
WO2000035483A1 (fr) * 1998-12-15 2000-06-22 The Brigham And Women's Hospital, Inc. Techniques et produits permettant de reguler l'activation du complement associee a la voie du complement a lectine

Also Published As

Publication number Publication date
AU6637000A (en) 2001-03-13
CA2380979A1 (fr) 2001-02-22
AU781805B2 (en) 2005-06-16
WO2001012212A1 (fr) 2001-02-22
EP1204419A1 (fr) 2002-05-15

Similar Documents

Publication Publication Date Title
US20230112931A1 (en) Plasma kallikrein binding proteins
CA2597717C (fr) Anticorps contre cxcr4 et leurs procedes d'utilisation
US7273925B1 (en) Methods and products for regulating lectin complement pathway associated complement activation
JP2003507338A (ja) レクチン補体経路（ｌｃｐ）のインヒビターおよびその使用
US20150239965A1 (en) Treatment
CN102985106A (zh) 用于治疗德戈斯病的方法和组合物
HUE026042T2 (en) Complement inhibition for improved nerve regeneration
EP1140171A1 (fr) Techniques et produits permettant de reguler l'activation du complement associee a la voie du complement a lectine
KR20190085935A (ko) 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도
US20220403014A1 (en) Compositions and methods of treating thrombosis
US20210179717A1 (en) Antibodies against mac-1
US20050163781A1 (en) Tissue adhesion formation control
KR102159412B1 (ko) 염증 질환 치료제
JP2006516024A (ja) α１β１インテグリンの誘導性リガンドおよび使用
O'Sullivan An investigation of the role of ACTN1 in platelet formation and of platelet function in myeloma
KR101268562B1 (ko) Ｔｌｔ-6 단백질에 대한 항체 및 그 응용

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20071106